Videos

Featured

Broadcast

Prevention & Chronic Conditions

Heart Failure
Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care

Vijay Chopra, Javed Butler, Dinesh Khullar , et al

Watch time: 1h 4m 2s

Nir Uriel

Watch time: 34m 39s (5 videos)
The Future of Heart Failure With Dr Yancy

Clyde W Yancy

Watch time: 9m 15s

Jasper J Brugts

Watch time: 2m 59s (15 videos)
AHA 25: HFpEF as an Adipose Tissue Disorder

Milton Packer

Watch time: 5m 43s
AHA 25 Late-breaking Discussion: Analysis from the SURPASS-CVOT Trial

Harriette Van Spall, Stephen Nicholls

Watch time: 12m 43s
AHA 25: The POLY-HF Trial

Ambarish Pandey

Watch time: 4m 15s
ESC 25 Hot Line Discussion: VICTOR: Vericiguat in Heart Failure

Harriette Van Spall, Faiez Zannad

Watch time: 13m 4s
ESC HF 25: The VELOCITY Study

Stephen J Greene

Watch time: 5m 30s
ESC 25: The REBOOT-CNIC Trial

Borja Ibanez

Watch time: 3m 53s
AHA 25: MAPLE-HCM Responder Analysis

Andrew Wang

Watch time: 3m
Optimising Heart Failure Therapy in 2026: Making GDMT Real

Stephen J Greene

Watch time: 4m 8s
High‑Stakes CKM Heart Failure Decisions

Robert Mentz

Watch time: 7m 27s
Phenotypes to Alerts in Heart Failure

Isabella Kardys

Watch time: 7m 56s
AI in Heart Failure Care: Tools Ready for Clinical Use

Lin Yee Chen

Watch time: 5m 23s
Practice‑Changing Therapies for HFpEF/HFmrEF: SGLT2i, MRAs and Incretin Trials

Harriette Van Spall, Maja Cikes

Watch time: 22m 28s

Broadcast

CV Disease in Special Populations

Guidelines & Statements
Defining Therapeutic Success in ATTR-CM

Margot K Davis, Marianna Fontana, Esther González López , et al

Watch time: 1h 1m 13s

Alessia Argirò, Juan Pablo Ochoa, Juan-Pablo Kaski, et al

Watch time: 6h 36m 27s (11 videos)
Biomarkers in heart failure: What’s new, tried, and true?

Harriette Van Spall, James L Januzzi

Watch time: 17m